Siren LLC’s Aclaris Therapeutics ACRS Stock Holding History

Siren LLC’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.7M	Buy	+2,025,000	New	+$11.6M	0.25%	69

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Siren LLC's ACRS Position: Q3 2026 in Review

Siren LLC opened a new position in Aclaris Therapeutics (ACRS) in Q3 2026: 2,025,000 shares worth $10.7M. The stake represents 0.25% of the portfolio and ranks #69 among its holdings.

82 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

Siren LLC held 2,025,000 shares of Aclaris Therapeutics worth $10.7M as of Q3 2026.
Aclaris Therapeutics was a new Siren LLC position in Q3 2026.
Aclaris Therapeutics made up 0.25% of Siren LLC's portfolio in Q3 2026, its #69 holding.
82 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Siren LLC's 13F filing for Q3 2026, filed 12 Nov 2026.